Ryusuke Hatae

List of Publications by Year
in descending order

53 papers	1,240 citations	516710 16 h-index	395702 33 g-index
56 all docs	56 docs citations	56 times ranked	2249 citing authors

#	Article	IF	Citations
1	Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro-Oncology, 2022, 24, 259-272.	1.2	6
2	Gamma distribution model of diffusion MRI for evaluating the isocitrate dehydrogenase mutation status of glioblastomas. British Journal of Radiology, 2022, 95, 20210392.	2.2	0
3	A case of ganglioglioma grade 3 with <scp>H3 K27M</scp> mutation arising in the medial temporal lobe in an elderly patient. Neuropathology, 2022, , .	1.2	4
4	Changes in the Relapse Pattern and Prognosis of Glioblastoma After Approval of First-Line Bevacizumab: A Single-Center Retrospective Study. World Neurosurgery, 2022, 159, e479-e487.	1.3	2
5	Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. Journal of Neuro-Oncology, 2021, 152, 47-54.	2.9	27
6	Mesenchymal glioblastoma-induced mature de-novo vessel formation of vascular endothelial cells in a microfluidic device. Molecular Biology Reports, 2021, 48, 395-403.	2.3	14
7	Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment. Cancers, 2021, 13, 758.	3.7	20
8	Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDHâ€wildtype glioblastoma. Cancer Medicine, 2021, 10, 3177-3187.	2.8	21
9	Current trend in treatment of glioblastoma in Japan: a national survey using the diagnostic procedure combination database (J-ASPECT study-glioblastoma). International Journal of Clinical Oncology, 2021, 26, 1441-1449.	2.2	3
10	Acute aortic dissection associated with wildâ€type transthyretin amyloid. Pathology International, 2021, 71, 556-558.	1.3	1
11	CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma. Frontiers in Immunology, 2021, 12, 670131.	4.8	13
12	Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathology, 2021, 38, 210-217.	1.7	6
13	Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma. Journal of Neuro-Oncology, 2021, 154, 187-196.	2.9	8
14	Intraventricular mucinâ€producing glioblastoma arising in the septum pellucidum at the frontal horn of the lateral ventricle: A case report. Neuropathology, 2021, 41, 381-386.	1.2	2
15	B cell-derived GABA elicits IL-10+ macrophages toÂlimit anti-tumour immunity. Nature, 2021, 599, 471-476.	27.8	145
16	Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800.	2.2	120
17	A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient. Neuropathology, 2020, 40, 99-103.	1.2	5
18	TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathologica Communications, 2020, 8, 201.	5.2	27

#	Article	IF	Citations
19	Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors. Scientific Reports, 2020, 10, 16162.	3.3	12
20	Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma. Pharmaceuticals, 2020, 13, 470.	3.8	9
21	First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. Journal of Neuro-Oncology, 2020, 146, 451-458.	2.9	16
22	HGG-24. HIGH-GRADE GLIOMA WITH A NOVEL FUSION GENE OF VCL-ALK. Neuro-Oncology, 2020, 22, iii348-iii348.	1.2	2
23	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight, 2020, 5, .	5.0	58
24	TBIO-08. BASE-RESOLUTION METHYLOMES OF GLIOMAS BEARING HISTONE H3.3 MUTATIONS REVEAL A G34 MUTANT-SPECIFIC SIGNATURE SHARED WITH BONE TUMORS. Neuro-Oncology, 2020, 22, iii468-iii468.	1.2	0
25	MPC-06 Cutting-edge of Cancer Genomic Medicine for brain tumors. Neuro-Oncology Advances, 2020, 2, ii12-ii12.	0.7	0
26	ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application. Neuro-Oncology Advances, 2020, 2, ii7-ii8.	0.7	0
27	IM-03 CD206 expression in peripheral blood-derived induced-microglia-like cells as a surrogate biomarker for the specific immune microenvironment of glioma. Neuro-Oncology Advances, 2020, 2, ii7-ii7.	0.7	1
28	Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Scientific Reports, 2019, 9, 10144.	3.3	29
29	Correlation between prognosis of glioblastoma and choline/N-acetyl aspartate ratio in MR spectroscopy. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2019, 18, 100498.	0.3	0
30	Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification. Clinical Neurology and Neurosurgery, 2019, 187, 105556.	1.4	7
31	Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagnostic and Interventional Imaging, 2019, 100, 411-419.	3.2	20
32	ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT. Neuro-Oncology Advances, 2019, 1, ii15-ii15.	0.7	0
33	The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy. World Neurosurgery, 2018, 114, e735-e742.	1.3	2
34	Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. Brain Tumor Pathology, 2018, 35, 81-89.	1.7	19
35	Highâ€resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas. Neuropathology, 2018, 38, 3-10.	1.2	18
36	Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. Pathology International, 2018, 68, 567-573.	1.3	8

#	Article	IF	Citations
37	An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. Neuropathology, 2018, 38, 493-497.	1.2	3
38	Insular primary glioblastomas with IDH mutations: Clinical and biological specificities. Neuropathology, 2017, 37, 200-206.	1.2	12
39	Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathology, 2017, 34, 103-112.	1.7	69
40	A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology, 2017, 37, 191-199.	1.2	33
41	Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. OncoTargets and Therapy, 2017, Volume 10, 429-437.	2.0	15
42	Deferred radiotherapy and upfront procarbazine–ACNU–vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade. OncoTargets and Therapy, 2016, Volume 9, 7123-7131.	2.0	11
43	Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS ONE, 2016, 11, e0160489.	2.5	39
44	Current Trends and Healthcare Resource Usage in the Hospital Treatment of Primary Malignant Brain Tumor in Japan: A National Survey Using the Diagnostic Procedure Combination Database (J-ASPECT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	1
45	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathologica Communications, 2016, 4, 79.	5.2	189
46	MR Imagingâ€“Based Analysis of Glioblastoma Multiforme: Estimation ofIDH1Mutation Status. American Journal of Neuroradiology, 2016, 37, 58-65.	2.4	109
47	Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression. Journal of Neuro-Oncology, 2015, 125, 33-41.	2.9	8
48	Genetic Analysis of a Case of Glioblastoma with Oligodendroglial Component Arising During the Progression of Diffuse Astrocytoma. Pathology and Oncology Research, 2015, 21, 839-843.	1.9	1
49	Visionary Approach for the Treatment of Brain Tumors. Japanese Journal of Neurosurgery, 2015, 24, 693-698.	0.0	1
50	Trochlear Nerve Schwannoma with Intratumoral Hemorrhage Presenting with Persistent Hiccups: A Case Report. Journal of Neurological Surgery Reports, 2014, 75, e183-e188.	0.6	14
51	QUANTIFICATION OF PRONEURAL GENE-EXPRESSION SIGNATURE OF GLIOMAS AND GLIOBLASTOMA-DERIVED SPHERES. Neuro-Oncology, 2014, 16, iii51-iii51.	1.2	0
52	A Rare Case of Chiari Type-1 Malformation Accompanied by Symptomatic Cerebrospinal Fluid Hypovolemia: Comparison of Congenital Chiari Type-1 Malformation and Acquired Chiari Malformation Secondary to Cerebrospinal Fluid Hypovolemia: Case Report. Neurologia Medico-Chirurgica, 2014, 54, 558-562.	2.2	9
53	Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Frontiers in Oncology, 2012, 2, 186.	2.8	88